Edwards Lifesciences announced that Theodora “Doretta” Mistras will become the company’s corporate vice president and chief financial officer, succeeding Scott Ullem. Mistras, who has served as CFO at Viatris since March 2024, will assume the role on May 29, 2026, following Ullem’s planned transition that was disclosed in October 2025.
The company’s most recent quarterly results, released in Q1 2026, showed sales of $1.65 billion, up 16.7% year‑over‑year, and an adjusted earnings per share of $0.78, beating the consensus estimate of $0.73 by $0.05. Management raised its full‑year 2026 sales guidance to 9%–11% and adjusted EPS guidance to $2.95–$3.05, reflecting confidence in continued demand and cost discipline.
Segment data highlighted that Transcatheter Aortic Valve Replacement (TAVR) sales grew 14.4% to $1.20 billion, while Transcatheter Mitral and Tricuspid Therapies (TMTT) reached $173 million. Operating profit margin for the quarter was 29.0%, with an adjusted margin of 31.4%, indicating that the company maintained strong profitability despite the broader market environment.
During the earnings call, CEO Bernard Zovighian emphasized that the company’s focused strategy has delivered “another strong quarter in Q1, achieving 12.7% sales growth,” underscoring the durability of its growth drivers. CFO Scott Ullem noted that the company is raising its full‑year guidance, citing robust demand and effective cost management.
The appointment of Mistras signals continuity in financial leadership and reinforces Edwards Lifesciences’ commitment to capital allocation and shareholder returns while preserving a strong balance sheet. Her experience as CFO at Viatris and background in healthcare investment banking positions her to support the company’s ongoing growth initiatives and strategic priorities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.